Correlation of retention of tumor methylmercaptopurine riboside-5′-phosphate with effectiveness in CD8F1 murine mammary tumor regression

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 621-627

  Dee Nord, L ^a   Stolfi, Robert L ^a   Colofiore, Joseph R ^a   Martin, Daniel S ^a  

^a Department of Cancer Research ^*

Author keywords

6 aminonicotinamide; Iodotubercidin; Mammary carcinoma; Methylmercaptopurine riboside; N (phosphonacetyl) L aspartic acid; Tumor regression

Indexed keywords

5 IODOTUBERCIDIN; 6 AMINONICOTINAMIDE; ADENOSINE KINASE INHIBITOR; ENZYME INHIBITOR; METHYLMERAPTOPURINE RIBOSIDE; METHYLMERCAPTOPURINE RIBOSIDE 5' PHOSPHATE; PURINE NUCLEOTIDE; SPARFOSIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER GRAFT; COLON TUMOR; CONTROLLED STUDY; DRUG RETENTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE LEVEL; TUMOR REGRESSION;

6-AMINONICOTINAMIDE; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLTHIOINOSINE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PHOSPHONOACETIC ACID;

EID: 0042285367     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02197-3     Document Type: Article

References (41)

1. Marks DI and Fox RM, DNA damage, poly ADP-ribosylation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42: 1859-1867, 1990.
2. Carson DA, Seto S, Wasson DB and Carrera CJ, DNA strand breaks, NAD metabolism and programmed cell death. Exp Cell Res 164: 273-281, 1986.
3. Gaal JC, Smith KR and Pearson CK, Cellular euthanasia mediated by a nuclear enzyme: A central role for nuclear ADP-ribosylation in cellular metabolism. Trends Biochem Sci 12: 129-132, 1987.
4. Tanizawa A, Kubota M, Takimoto T, Akiyama Y, Seto S, Kiriyama Y and Mikawa H, Prevention of adriamycin-induced interphase death by 3-aminobenzamide and nicotinamide in a human promyelocytic cell line. Biochem Biophys Res Commun 144: 1031-1036, 1987.
5. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG and Cochrane CG, Oxidant injury of cells: DNA strand breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 77: 1312-1322, 1986.
6. Berger NA and Berger SJ, Metabolic consequences of DNA damage: The role of poly (ADP-ribose) polymerase as mediator of the suicide response. In: Mechanisms of DNA Damage and Repair (Eds. Grossman L and Upton AC), pp. 357-363. Plenum Publishing, New York, 1986.
7. Martin DS, Purine and pyrimidine biochemistry and some relevant clinical and preclinical cancer chemotherapy research. In: Metabolism and Action of Anti-cancer Drugs (Eds. Powis G and Prough RA), pp. 91-140. Taylor & Francis, New York, 1987.
8. Stolfi RL, Colofiore JR, Nord LD, Koutcher JA and Martin DS, Biochemical modulation of tumor cell energy: Regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res 52: 4074-4081, 1992.
9. Martin DS, Stolfi RL, Colofiore JR, Koutcher JA, Alfieri AA, Sternberg SS and Nord LD, Apoptosis resulting from anticancer agent activity in vivo is enhanced by biochemical modulation of tumor cell energy. In: Programmed Cell Death. The Cellular and Molecular Biology of Apoptosis (Eds. Lavin M and Watters D), pp. 279-296. Harwood, Switzerland, 1993.
10. Martin DS, Stolfi RL, Colofiore JR, Nord LD and Sternberg S, Biochemical modulation of tumor cell energy in vivo: II. A lower dose of Adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest 12: 296-307, 1994.
11. Stolfi RL, Colofiore JR, Nord LD and Martin DS, Enhanced antitumor activity of an Adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Anticancer Drugs, in press.
12. Koutcher JA, Alfieri AA, Stolfi RL, Devitt ML, Colofiore JR, Nord LD and Martin DS, Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res 53: 3518-3523, 1993.
13. Zimmerman TP, Chu L-C, Buggé CJL, Nelson DJ, Miller RL and Elion GB, Formation of 5′-nucleotides of 6-methylmercaptopurine ribonucleoside in human tissue in vitro. Biochem Pharmacol 23: 2737-2749, 1974.
14. Warnick CT and Paterson ARP, Effect of methylthioinosine on nucleotide concentrations in L5178Y cells. Cancer Res 33: 1711-1715, 1973.
15. Woods RA, Henderson RM and Henderson JF, Consequences of inhibition of purine biosynthesis de novo by 6-methylmercapto-purine riboside in cultured lymphoma L5178Y cells. Eur J Cancer 14: 765-770, 1978.
16. Newby A, Interaction of inhibitors with adenosine-metabolizing enzymes in intact isolated cells. Biochem Pharmacol 30: 2611-2617, 1981.
17. Stolfi RL, Martin DS and Fugman RA, Spontaneous murine mammary adenocarcinoma: Model system for the evaluation of combined methods of therapy. Cancer Chemother Rep (Part 1), 55: 239-251, 1971.
18. Martin DS, Fugman RA, Stolfi RL and Hayworth PE, Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep (Part 2), 5: 89-109, 1975.
19. Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE and DeVita VT Jr, Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17: 129-142, 1991.
20. Khym JX, An analytical system for rapid separation of tissue nucleotides at low pressure on conventional anion exchangers. Clin Chem21: 1245-1252, 1975.
21. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
22. Yen RCK, Raivio KO and Becker MA, Inhibition of phosphoribosylpyrophosphate synthesis in human fibroblasts by 6-methylthioinosinate. J Biol Chem 256: 1839-1845, 1981.
23. Brown GC, Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 284: 1-13, 1992.
24. Eigenbrodt E and Glossmann H, Glycolysis - one of the keys to cancer? Trends Pharmacol Sci 1: 240-245, 1980.
25. Schaefer C, Mayer W-K, Kruger W and Vaupel P, Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumors upon local hyperthermia and/or hyperglycemia. J Cancer Res Clin Oncol 119: 599-608, 1993.
26. Hyslop PA, Hinshaw DB, Halsey WA, Schraufstatter IU, Sauerheber RD, Spragg RG, Jackson JH and Cochrane CG, Mechanisms of oxidant-mediated cell injury: The glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem 263: 1665-1675, 1988.
27. Carson DA, Seto S and Wasson DB, Pyridine nucleotide cycling and poly(ADP-ribose) synthesis in resting human lymphocytes. J Immunol 138: 1904-1907, 1987.
28. Kohler E, Barrach H-J and Neubert D, Inhibition of NADP-dependent oxioreductases by the 6-aminonicotinamide analogue of NADP. FEBS Lett 6: 225-228, 1970.
29. Hunting D, Gowans B and Henderson JF, Effects of 6-amino-nicotinamide on cell growth, poly (ADP-ribose) synthesis and nucleotide metabolism. Biochem Pharmacol 34: 3999-4003, 1985.
30. Caldwell IC, Henderson JF and Paterson ARP, The enzymatic formation of 6-(methylmercapto)purine ribonucleoside 5′-phosphate. Can J Biochem 44: 229-245, 1966.
31. Berry MA, Reynolds JE and Eastman A, Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 53: 2349-2357, 1993.
32. Li J and Eastman A, Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. J Biol Chem 270: 3202-3211, 1995.
33. Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G and Carson DA, New adenosine kinase inhibitors with oral antiinflammatory activity: Synthesis and biological evaluation. J Med Chem 36: 3424-3430, 1993.
34. Firestein G, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B and Mullane KM, Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152: 5853-5861, 1994.
35. Sciotti VM and Van Wylen DGL, Increases in interstitial adenosine and cerebral blood flow with inhibition of adenosine kinase and adenosine deaminase. J Cereb Blood Flow Metab 13: 201-207, 1993.
36. Massillon D, Stalmans W, Van De Werve G and Bollen M, Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J 299: 123-128, 1994.
37. Phillips E and Newsholme EA, Maximum activities, properties and distribution of 5′ nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J Neurochem 33: 553-558, 1979.
38. Mistry G and Drummond GI, Adenosine metabolism in microvessels from heart and brain. J Mol Cell 18: 13-22, 1986.
39. +-ATPase shows complex kinetics independently of the degree of purification. Biochim Biophys Acta 1153: 283-288, 1993.
40. Sokoloski JA and Sartorelli AC, Inhibition of the synthesis of glycoproteins and induction of the differentiation of HL-60 promyelocytic leukemia cells by 6-methylmercaptopurine ribonucleoside. Cancer Res 47: 6283-6287, 1987.
41. Nguyen BT, El Sayed YM and Sadée W, Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells. Cancer Res 44: 2272-2277, 1984.